Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study.
Mina R, Belotti A, Petrucci MT, Zambello R, Capra A, Di Lullo G, Ronconi S, Pescosta N, Grasso M, Monaco F, Cellini C, Gobbi M, Ballanti S, de Fabritiis P, Mosca-Siez ML, Marchetti M, Liberati AM, Offidani M, Giuliani N, Ria R, Musto P, Romano A, Sonneveld P, Boccadoro M, Larocca A. Mina R, et al. Among authors: petrucci mt. Blood Cancer J. 2020 May 18;10(5):58. doi: 10.1038/s41408-020-0326-1. Blood Cancer J. 2020. PMID: 32424154 Free PMC article. Clinical Trial. No abstract available.
Alpha-2b recombinant interferon (Intron-A) as maintenance treatment in multiple myeloma.
Avvisati G, Petrucci MT, Pulsoni A, Tribalto M, Lauta VM, Gernone A, Boccadoro M, Marmont F, Pileri A, Dammacco F, et al. Avvisati G, et al. Among authors: petrucci mt. Eur J Haematol Suppl. 1990;52:9-11. doi: 10.1111/j.1600-0609.1990.tb00897.x. Eur J Haematol Suppl. 1990. PMID: 2279547 Clinical Trial. No abstract available.
[Therapy of multiple myeloma].
La Verde G, Pulsoni A, Petrucci MT, Mandelli F. La Verde G, et al. Among authors: petrucci mt. Recenti Prog Med. 1997 Apr;88(4):186-93. Recenti Prog Med. 1997. PMID: 9206817 Review. Italian.
Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cells in patients with multiple myeloma.
Petrucci MT, Avvisati G, La Verde G, De Fabritiis P, Ribersani M, Palumbo G, De Felice L, Rusignuolo A, Simone F, Meloni G, Mandelli F. Petrucci MT, et al. Acta Haematol. 2003;109(4):184-8. doi: 10.1159/000070967. Acta Haematol. 2003. PMID: 12853690
Endothelial cells in the bone marrow of patients with multiple myeloma.
Vacca A, Ria R, Semeraro F, Merchionne F, Coluccia M, Boccarelli A, Scavelli C, Nico B, Gernone A, Battelli F, Tabilio A, Guidolin D, Petrucci MT, Ribatti D, Dammacco F. Vacca A, et al. Among authors: petrucci mt. Blood. 2003 Nov 1;102(9):3340-8. doi: 10.1182/blood-2003-04-1338. Epub 2003 Jul 10. Blood. 2003. PMID: 12855563 Free article.
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial.
Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, Lauta VM, Bergonzi C, Barbui A, Caravita T, Capaldi A, Pregno P, Guglielmelli T, Grasso M, Callea V, Bertola A, Cavallo F, Falco P, Rus C, Massaia M, Mandelli F, Carella AM, Pogliani E, Liberati AM, Dammacco F, Ciccone G, Boccadoro M. Palumbo A, et al. Among authors: petrucci mt. Blood. 2004 Nov 15;104(10):3052-7. doi: 10.1182/blood-2004-02-0408. Epub 2004 Jul 20. Blood. 2004. PMID: 15265788 Free article. Clinical Trial.
256 results